[VIRTUAL] Oncolytic Vaccinia (Olvi-Vec) Primed Immunochemotherapy in Platinum- Resistant/Refractory Ovarian Cancer

[VIRTUAL] Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial

[VIRTUAL] The Metaxas’s Hospital THromboprophylaxis program in Oncological & Surgical Patients – MeTHOS [ClinicalTrials.gov: NCT04248348]. Intermediate results for gynecological cancer patients undergoing surgery.

[VIRTUAL] Avelumab in combination with and/or following chemotherapy vs chemotherapy in treatment-naive patients with ovarian cancer: biomarker analyses from the phase 3 JAVELIN Ovarian 100 trial

[VIRTUAL] Efficacy and Safety of Lenvatinib Plus Pembrolizumab in Patients with Previously Treated Ovarian Cancer in the Multicohort Phase 2 LEAP-005 Study

[VIRTUAL] Postprogression Efficacy Outcomes From the Phase 3 ARIEL3 Study of Rucaparib in Patients With Platinum-Sensitive Recurrent Ovarian Carcinoma Associated With Either BRCA1 or BRCA2 Mutations

[VIRTUAL] Efficacy on Individualized Starting Dose (ISD) and Fixed Starting Dose (FSD) of Niraparib per Investigator-Assessment (IA) in Newly Diagnosed Advanced Ovarian Cancer (OC)

[VIRTUAL] Quality-adjusted (QA) progression-free survival analyses of veliparib + carboplatin/paclitaxel (CP) vs CP alone in patients with newly diagnosed ovarian cancer

[VIRTUAL] Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial

[VIRTUAL] Results of a Randomized Phase II Trial of Paclitaxel and Carboplatin Versus Bleomycin, Etoposide and Cisplatin for Newly Diagnosed and Recurrent Chemonaive Stromal Ovarian Tumors

[VIRTUAL] Phase 1 Dose-Escalation Study of STRO-002, an anti-Folate Receptor alpha (FRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Platinum- Resistant/Refractory Epithelial Ovarian Cancer (OC).

[VIRTUAL] ENGOT-cx11/GOG 3047/KEYNOTE-A18: A Phase 3, Randomized, Double-blind Study of Pembrolizumab With Chemoradiotherapy in Patients With High-Risk Locally Advanced Cervical Cancer

[VIRTUAL] Camrelizumab combined with apatinib for refractory gestational trophoblastic neoplasia: A phase 2, single-arm, prospective Study

[VIRTUAL] An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum- Resistant Ovarian Cancer

[VIRTUAL] ENGOT-en9/LEAP-001: A Phase 3 Study of First-line Pembrolizumab Plus Lenvatinib Compared With Chemotherapy in Advanced or Recurrent Endometrial Cancer